Secukinumab Clinical Trials
7 recruitingDrug
Phase 31Phase 11
Showing 1–7 of 7 trials
Recruiting
Phase 3
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Polymyalgia Rheumatica
Novartis Pharmaceuticals288 enrolled115 locationsNCT06331312
Recruiting
Phase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Juvenile Psoriatic Arthritis
Novartis Pharmaceuticals20 enrolled7 locationsNCT06751238
Recruiting
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Hidradenitis SuppurativaJuvenile Idiopathic ArthritisPediatric Plaque Psoriasis
Novartis Pharmaceuticals76 enrolled1 locationNCT07243782
Recruiting
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
Ankylosing Spondylitis
Novartis Pharmaceuticals70 enrolled2 locationsNCT06905288
Recruiting
Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
Hidradenitis Suppurativa
Novartis Pharmaceuticals300 enrolled20 locationsNCT06517732
Recruiting
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
Peking Union Medical College50 enrolled1 locationNCT07109765
Recruiting
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
DepressionPsoriatic ArthritisPsoriatic Plaque
NHS Greater Glasgow and Clyde50 enrolled1 locationNCT06786936